Long-awaited federal funding has been approved for a first-of-its-kind, Boston-led study to test whether drugs can hold off Alzheimer’s disease in people who have no symptoms of the illness, but who have an abnormal protein in their brains believed to be a hallmark of the disease. Reisa Sperling, HMS professor of neurology at Brigham and Women’s Hospital, will lead the clinical trial.
